Skip to main content
Fig. 5 | Renal Replacement Therapy

Fig. 5

From: Linagliptin inhibits lipopolysaccharide-stimulated interleukin-6 production, intranuclear p65 expression, and p38 mitogen-activated protein kinase phosphorylation in human umbilical vein endothelial cells

Fig. 5

Interleukin (IL)-6 production after linagliptin and protein kinase A inhibitor (H89) treatment. Human umbilical vein endothelial cells (HUVECs) were treated with lipopolysaccharide and/or linagliptin and H89. IL-6 levels in the supernatants were determined by ELISA after 5 h of treatment. **P < 0.01 vs. control; ## P < 0.01 vs. LPS 1 μg/mL; P < 0.05 vs. LPS 1 μg/mL and 50 nM linagliptin. Lina linagliptin

Back to article page